SCHEMBL29894065

SCHEMBL29894065

COC(=O)c1cc(F)cc(F)c1[N+](=O)[O-]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
PDGFRB P09619 1/20 0.40
FGFR1 P11362 1/20 0.40
PDGFRA P16234 1/20 0.40
FLT1 P17948 1/20 0.40
FGFR3 P22607 1/20 0.40
KDR P35968 1/20 0.40
COMT P21964 1/20 0.39
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
PKM P14618 1/20 0.38
TTR P02766 1/20 0.38
TDP1 Q9NUW8 2/20 0.38
KMT2A Q03164 3/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1202856 1.00 SMN1; SMN2 (0.42) SMN1; SMN2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL1005723 0.86 SMN1; SMN2 (0.41) SMN1; SMN2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL1056662 0.86 MEN1 (0.45) SMN1; SMN2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL1202303 0.86 KDM4E (0.42) SMN1; SMN2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL26988941 0.84 PDGFRB (0.41) SMN1; SMN2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL30722742 0.84 PDGFRB (0.41) SMN1; SMN2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL1202724 0.83 ALDH1A1 (0.46) SMN1; SMN2KMT2AALDH1A1MEN1NPC1
SCHEMBL31423850 0.80 PKM (0.45) CES2CES1PKMTTRTDP1
SCHEMBL1202494 0.80 PKM (0.45) CES2CES1PKMTTRTDP1
SCHEMBL7009698 0.78 PDGFRB (0.41) SMN1; SMN2PDGFRBFGFR1PDGFRAFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115023419-A Cereblon-bound piperidine-2, 6-diones and methods of use thereof 凯普托尔治疗学股份有限公司 2022-09-06 CN disclosed